Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas

Lorella Maniscalco, Yolanda Millán, Selina Iussich, Mauro Denina, Raquel Sánchez-Céspedes, Francesca Gattino, Bartolomeo Biolatti, Nobuo Sasaki, Takayuki Nakagawa, Maria Flavia Di Renzo, Juana Martín de las Mulas, Raffaella De Maria

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Triple negative breast cancer (TNBC) in humans is defined by the absence of oestrogen receptor (ER), progesterone receptor (PR) and HER2 overexpression. Mammalian target of rapamycin (mTOR) is overexpressed in TNBC and it represents a potential target for the treatment of this aggressive tumour. Feline mammary carcinoma (FMC) is considered to be a model for hormone-independent human breast cancer. This study investigated mTOR and p-mTOR expression in FMC in relation to triple negative (TN) phenotype.Results: The expression of mTOR, p-mTOR, ERα, PR and HER2 was evaluated in 58 FMCs by immunohistochemistry and in six FMC cell lines by Western blot analysis. 53.5% of FMC analyzed were ER, PR, HER2 negative (TN-FMC) while 56.9% and 55.2% of cases expressed mTOR and p-mTOR respectively. In this study we found that m-TOR and p-mTOR were more frequently detected in TN-FMC and in HER2 negative samples.Conclusions: In this study, we demonstrate that there is also a FMC subset defined as TN FMC, which is characterised by a statistically significant association with m-TOR and p-mTOR expression as demonstrated in human breast cancer.

Original languageEnglish
Article number80
JournalBMC Veterinary Research
Volume9
DOIs
Publication statusPublished - Apr 15 2013

Fingerprint

Felidae
Sirolimus
breast neoplasms
cats
Breast Neoplasms
Progesterone Receptors
Triple Negative Breast Neoplasms
Estrogen Receptors
Western Blotting
Immunohistochemistry
immunohistochemistry
Hormones
Western blotting
Phenotype
Cell Line
cell lines
hormones

ASJC Scopus subject areas

  • veterinary(all)
  • Medicine(all)

Cite this

Maniscalco, L., Millán, Y., Iussich, S., Denina, M., Sánchez-Céspedes, R., Gattino, F., ... De Maria, R. (2013). Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas. BMC Veterinary Research, 9, [80]. https://doi.org/10.1186/1746-6148-9-80

Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas. / Maniscalco, Lorella; Millán, Yolanda; Iussich, Selina; Denina, Mauro; Sánchez-Céspedes, Raquel; Gattino, Francesca; Biolatti, Bartolomeo; Sasaki, Nobuo; Nakagawa, Takayuki; Di Renzo, Maria Flavia; de las Mulas, Juana Martín; De Maria, Raffaella.

In: BMC Veterinary Research, Vol. 9, 80, 15.04.2013.

Research output: Contribution to journalArticle

Maniscalco, L, Millán, Y, Iussich, S, Denina, M, Sánchez-Céspedes, R, Gattino, F, Biolatti, B, Sasaki, N, Nakagawa, T, Di Renzo, MF, de las Mulas, JM & De Maria, R 2013, 'Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas', BMC Veterinary Research, vol. 9, 80. https://doi.org/10.1186/1746-6148-9-80
Maniscalco L, Millán Y, Iussich S, Denina M, Sánchez-Céspedes R, Gattino F et al. Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas. BMC Veterinary Research. 2013 Apr 15;9. 80. https://doi.org/10.1186/1746-6148-9-80
Maniscalco, Lorella ; Millán, Yolanda ; Iussich, Selina ; Denina, Mauro ; Sánchez-Céspedes, Raquel ; Gattino, Francesca ; Biolatti, Bartolomeo ; Sasaki, Nobuo ; Nakagawa, Takayuki ; Di Renzo, Maria Flavia ; de las Mulas, Juana Martín ; De Maria, Raffaella. / Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas. In: BMC Veterinary Research. 2013 ; Vol. 9.
@article{24e8a4d234f441ac8224b8d5f77b2642,
title = "Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas",
abstract = "Background: Triple negative breast cancer (TNBC) in humans is defined by the absence of oestrogen receptor (ER), progesterone receptor (PR) and HER2 overexpression. Mammalian target of rapamycin (mTOR) is overexpressed in TNBC and it represents a potential target for the treatment of this aggressive tumour. Feline mammary carcinoma (FMC) is considered to be a model for hormone-independent human breast cancer. This study investigated mTOR and p-mTOR expression in FMC in relation to triple negative (TN) phenotype.Results: The expression of mTOR, p-mTOR, ERα, PR and HER2 was evaluated in 58 FMCs by immunohistochemistry and in six FMC cell lines by Western blot analysis. 53.5{\%} of FMC analyzed were ER, PR, HER2 negative (TN-FMC) while 56.9{\%} and 55.2{\%} of cases expressed mTOR and p-mTOR respectively. In this study we found that m-TOR and p-mTOR were more frequently detected in TN-FMC and in HER2 negative samples.Conclusions: In this study, we demonstrate that there is also a FMC subset defined as TN FMC, which is characterised by a statistically significant association with m-TOR and p-mTOR expression as demonstrated in human breast cancer.",
author = "Lorella Maniscalco and Yolanda Mill{\'a}n and Selina Iussich and Mauro Denina and Raquel S{\'a}nchez-C{\'e}spedes and Francesca Gattino and Bartolomeo Biolatti and Nobuo Sasaki and Takayuki Nakagawa and {Di Renzo}, {Maria Flavia} and {de las Mulas}, {Juana Mart{\'i}n} and {De Maria}, Raffaella",
year = "2013",
month = "4",
day = "15",
doi = "10.1186/1746-6148-9-80",
language = "English",
volume = "9",
journal = "BMC Veterinary Research",
issn = "1746-6148",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas

AU - Maniscalco, Lorella

AU - Millán, Yolanda

AU - Iussich, Selina

AU - Denina, Mauro

AU - Sánchez-Céspedes, Raquel

AU - Gattino, Francesca

AU - Biolatti, Bartolomeo

AU - Sasaki, Nobuo

AU - Nakagawa, Takayuki

AU - Di Renzo, Maria Flavia

AU - de las Mulas, Juana Martín

AU - De Maria, Raffaella

PY - 2013/4/15

Y1 - 2013/4/15

N2 - Background: Triple negative breast cancer (TNBC) in humans is defined by the absence of oestrogen receptor (ER), progesterone receptor (PR) and HER2 overexpression. Mammalian target of rapamycin (mTOR) is overexpressed in TNBC and it represents a potential target for the treatment of this aggressive tumour. Feline mammary carcinoma (FMC) is considered to be a model for hormone-independent human breast cancer. This study investigated mTOR and p-mTOR expression in FMC in relation to triple negative (TN) phenotype.Results: The expression of mTOR, p-mTOR, ERα, PR and HER2 was evaluated in 58 FMCs by immunohistochemistry and in six FMC cell lines by Western blot analysis. 53.5% of FMC analyzed were ER, PR, HER2 negative (TN-FMC) while 56.9% and 55.2% of cases expressed mTOR and p-mTOR respectively. In this study we found that m-TOR and p-mTOR were more frequently detected in TN-FMC and in HER2 negative samples.Conclusions: In this study, we demonstrate that there is also a FMC subset defined as TN FMC, which is characterised by a statistically significant association with m-TOR and p-mTOR expression as demonstrated in human breast cancer.

AB - Background: Triple negative breast cancer (TNBC) in humans is defined by the absence of oestrogen receptor (ER), progesterone receptor (PR) and HER2 overexpression. Mammalian target of rapamycin (mTOR) is overexpressed in TNBC and it represents a potential target for the treatment of this aggressive tumour. Feline mammary carcinoma (FMC) is considered to be a model for hormone-independent human breast cancer. This study investigated mTOR and p-mTOR expression in FMC in relation to triple negative (TN) phenotype.Results: The expression of mTOR, p-mTOR, ERα, PR and HER2 was evaluated in 58 FMCs by immunohistochemistry and in six FMC cell lines by Western blot analysis. 53.5% of FMC analyzed were ER, PR, HER2 negative (TN-FMC) while 56.9% and 55.2% of cases expressed mTOR and p-mTOR respectively. In this study we found that m-TOR and p-mTOR were more frequently detected in TN-FMC and in HER2 negative samples.Conclusions: In this study, we demonstrate that there is also a FMC subset defined as TN FMC, which is characterised by a statistically significant association with m-TOR and p-mTOR expression as demonstrated in human breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84876127232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876127232&partnerID=8YFLogxK

U2 - 10.1186/1746-6148-9-80

DO - 10.1186/1746-6148-9-80

M3 - Article

C2 - 23587222

AN - SCOPUS:84876127232

VL - 9

JO - BMC Veterinary Research

JF - BMC Veterinary Research

SN - 1746-6148

M1 - 80

ER -